Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia

PURPOSE: Tamoxifen administered for 5 years at 20 mg/d is effective in breast cancer treatment and prevention, but toxicity has limited its broad use. Biomarker trials showed that 5 mg/d is not inferior to 20 mg/d in decreasing breast cancer proliferation. We hypothesized that a lower dose given for...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Oncol
Main Authors: DeCensi, Andrea, Puntoni, Matteo, Guerrieri-Gonzaga, Aliana, Caviglia, Silvia, Avino, Franca, Cortesi, Laura, Taverniti, Cristiana, Pacquola, Maria Grazia, Falcini, Fabio, Gulisano, Marcella, Digennaro, Maria, Cariello, Anna, Cagossi, Katia, Pinotti, Graziella, Lazzeroni, Matteo, Serrano, Davide, Branchi, Daniela, Campora, Sara, Petrera, Marilena, Buttiron Webber, Tania, Boni, Luca, Bonanni, Bernardo
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2019
Subjects:
Original Reports
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6601429/
https://ncbi.nlm.nih.gov/pubmed/30973790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.01779
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items